Alnylam Pharmaceuticals, Inc.(ALNY)NASDAQ
Stock Performance & Returns
Peer Comparison
Relative scale, growth, and profitability vs sector peers
| Ticker | Market Cap | P/E Ratio | Revenue Growth | Net Margin | EPS | ROE | Debt/Equity | Dividend Yield | 52W High | 52W Low |
|---|---|---|---|---|---|---|---|---|---|---|
ALNY | 35.39 B | 45.45x | 66.90% | 16.13% | $5.82 | 96.56% | 2.21 | - | $495.55 | $197.81 |
GILD | 187.51 B | -57.06x | 10.20% | -10.64% | $-2.65 | -20.68% | 2.23 | 2.25% | $155.38 | $106.44 |
VRTX | 141.42 B | 32.33x | 12.50% | 35.00% | $17.26 | 23.54% | 9.77 | - | $555.69 | $374.17 |
REGN | 85.31 B | 20.87x | 16.70% | 27.87% | $40.42 | 14.04% | 8.54 | 47.00% | $847.00 | $538.24 |
950220.KQ | 17.27 B | - | 45.59% | - | - | -61.03% | 0.20 | - | $5465.00 | $1115.00 |
Peer Valuation & Performance Analysis
Peer group analysis for Alnylam Pharmaceuticals, Inc. (ALNY) compared to its primary competitors (including GILD, VRTX, REGN) reveals distinct metrics. ALNY trades at a valuation premium compared to its competitors, with a P/E ratio of 45.4x versus the peer average of -1.3x (representing a -3623% premium). This indicates that the market expects superior growth or commands a quality premium for ALNY. In terms of growth, ALNY's revenue growth of 66.9% exceeds the peer average of 21.2%, highlighting its competitive strength and market share gains. Additionally, its net margin of 16.1% is comparable to the peer average of 17.4%.
Peer Performance Rankings
Ranking comparison across key performance metrics
P/E Ratio (Lower is Better)
Revenue Growth
Net Profit Margin
Financial Rankings Summary
• ALNY ranks #3 in P/E ratio, #1 in revenue growth, and #3 in profit margins
• Average ranking: #2 - 🎯 Top-tier fundamentals relative to peer group
• Rankings based on actual financial data from company reports
Historical Trading Data
Price and volume data with customizable timeframes
Showing 15 of 15 trading sessions from the last 15 days
| Date | Open | High | Low | Close | Volume | Daily Change |
|---|---|---|---|---|---|---|
| 2026-09-03 | $265.94 | $271.19 | $261.54 | $264.50 | 1,709,100 | -0.54% |
| 2026-09-02 | $246.48 | $269.94 | $246.48 | $267.40 | 3,286,200 | +8.49% |
| 2026-09-01 | $242.40 | $248.13 | $238.00 | $246.11 | 1,941,200 | +1.53% |
| 2026-08-31 | $235.94 | $243.02 | $233.33 | $240.69 | 1,636,200 | +2.01% |
| 2026-08-28 | $224.47 | $239.08 | $223.61 | $237.10 | 1,847,000 | +5.63% |
| 2026-08-27 | $236.56 | $238.00 | $230.46 | $236.56 | 1,293,200 | - |
| 2026-08-26 | $238.54 | $242.89 | $236.60 | $239.00 | 1,116,200 | +0.19% |
| 2026-08-25 | $236.56 | $240.67 | $235.41 | $240.08 | 1,576,200 | +1.49% |
| 2026-08-24 | $235.83 | $237.91 | $228.59 | $236.01 | 2,134,900 | +0.08% |
| 2026-08-21 | $228.88 | $238.97 | $228.34 | $236.22 | 1,902,200 | +3.21% |
| 2026-08-20 | $239.00 | $240.88 | $228.74 | $229.30 | 1,701,700 | -4.06% |
| 2026-08-19 | $234.36 | $244.03 | $233.40 | $242.61 | 1,879,100 | +3.52% |
| 2026-08-18 | $226.27 | $230.91 | $222.01 | $228.61 | 1,600,200 | +1.03% |
| 2026-08-17 | $225.76 | $227.99 | $222.12 | $224.60 | 1,539,200 | -0.51% |
| 2026-08-14 | $223.52 | $228.98 | $220.23 | $228.65 | 1,525,800 | +2.30% |
Explore More Analysis for ALNY
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.